An observational study in Retinal Vascular and Normal Eyes, sponsored by Heidelberg Engineering GmbH. Completed at 1 site in United States. Open to participants aged 22 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-15.
Sponsored by Heidelberg Engineering GmbH (part of EssilorLuxottica) · Observational
Assessment of image quality and clinical relevance of OCT Angiography via comparison to FA/ICGA.
The objectives of this study are:
Heidelberg Engineering GmbH is the lead sponsor of 22 studies on the registry; 1 is open to participants now.
First submitted before Heidelberg Engineering GmbH became part of EssilorLuxottica.
Counted across the registry records on this site, refreshed daily.
Subjects with Normal Eyes:
Subjects with Pathology:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
All subjects:
Subjects with Normal Eyes:
Subjects with Pathology:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
OCT Angiography, Color Fundus Photography, and Fluorescein Angiography as per protocol in subjects without ophthalmic pathology.
Device: OCT Angiography · Device: Color Fundus Photography · Device: Fluorescein Angiography
OCT Angiography, Color Fundus Photography, Fluorescein Angiography, and when clinically indicated, Indocyaine Green Angiography as per protocol in subjects with retinal vascular pathology.
Device: OCT Angiography · Device: Color Fundus Photography · Device: Fluorescein Angiography · Device: Indocyaine Green Angiography
OCT Angiography offers clinicians a non-invasive three-dimensional visualization of vasculature in the retina and choroid. The visualization of perfused vasculature in a three-dimensional layout, offers clinicians an aid in the identification of retinal and choroidal pathologies such as retinal ischemia, microaneurysms, retinal neovascularization and choroidal neovascular membranes.
Also known as: OCTA
Non-contact white light photography.
Also known as: CFP
An imaging procedure where dye is injected into a vein and images are taken of the back of the eye to visualize the perfusion of retinal vessels in two dimensional images.
Also known as: FA
An imaging procedure where dye is injected into a vein and images are taken of the back of the eye to visualize the perfusion of choroidal vessels in two dimensional images.
Also known as: ICGA
OCTA image quality
Image quality grading results of study selected images
Time frame: day 1
Clinically relevant findings on OCTA
Clinically relevant grading results of study selected images
Time frame: day 1
Plan to share: No
No publications or documents are linked to this record.
Ran from Aug 2017 to primary completion in Jan 2018, 4 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.